Findings

What do systematic reviews say?

9 questions · 9 findings · 2 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 55.6%GRADE not reported 0 · 0%Very low 2 · 22.2%Low 2 · 22.2%Moderate 0 · 0%High 0 · 0%

Dopexamine vs dopamine

All‐cause long‐term mortality · adults with low cardiac output syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Enoximone vs dobutamine

All‐cause long‐term mortality · adults with low cardiac output syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Levosimendan vs placebo

All‐cause long‐term mortality: range 4 to 6 months · adults with cardiogenic shock or low cardiac output syndrome

It is very uncertain whether levosimendan changes all‐cause long‐term mortality: range 4 to 6 months compared with placebo (very low certainty).

1 finding from 1 review

Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
RR 0.55 [0.16, 1.9]
2 studies · 55 participants
Very low

Levosimendan vs dobutamine

All‐cause long‐term mortality: range 4 to 12 months · people with cardiogenic shock or low cardiac output syndrome

Levosimendan showed no clear difference in all‐cause long‐term mortality: range 4 to 12 months compared with dobutamine (low certainty).

1 finding from 1 review

Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
RR 0.84 [0.63, 1.13]
4 studies · 1591 participants
Low

Outpatient vs inpatient treatment

Long‐term all‐cause mortality · people with low‐risk acute pulmonary embolism

Outpatient showed no clear difference in long‐term all‐cause mortality compared with inpatient treatment (low certainty).

1 finding from 1 review

Outpatient versus inpatient treatment for acute pulmonary embolism 2022 · Cochrane Headline outcomes only
RR 0.98 [0.06, 15.58]
2 studies · 451 participants
Low

Dopamine‐milrinone vs dopamine‐dobutamine

All‐cause long‐term mortality · adults with cardiogenic shock

The review found no eligible studies for this question.

1 finding from 1 review

Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Levosimendan vs enoximone

All‐cause long‐term mortality · adults with cardiogenic shock

The review found no eligible studies for this question.

1 finding from 1 review

Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Epinephrine vs norepinephrine‐dobutamine

All‐cause long‐term mortality · adults with cardiogenic shock

The review found no eligible studies for this question.

1 finding from 1 review

Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Epinephrine vs norepinephrine

All‐cause long‐term mortality: 60 days · adults with cardiogenic shock

It is very uncertain whether epinephrine changes all‐cause long‐term mortality: 60 days compared with norepinephrine (very low certainty).

1 finding from 1 review

Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome 2020 · Cochrane Headline outcomes only
RR 1.41 [0.78, 2.56]
1 study · 57 participants
Very low